Department of Orthopedic Surgery, Mayo Clinic, Rochester, MN, USA.
Department of Orthopaedic Surgery, Department of Orthopedics Surgery & Rehabilitation, University of Wisconsin, Madison, WI 53705-2281, USA.
Clin Interv Aging. 2020 Jun 29;15:1023-1033. doi: 10.2147/CIA.S227611. eCollection 2020.
Osteoporosis is a common and debilitating condition characterized by diminished bone mass and architecture leading to bone fragility. Antiresorptive medicines like bisphosphonates (and less commonly denosumab) are the typical first-line agents for the medical treatment of osteoporosis. However, newer anabolic agents have been shown to improve bone mass and architecture, as well as reduce fracture risk, to a greater degree than traditional antiresorptive therapies. Teriparatide (human recombinant parathyroid hormone (PTH) 1-34, Forteo, Ely Lilly, Indianapolis, IN), which was the first in class to be approved in the United States, is the most widely used anabolic osteoporosis medicine and has shown significant benefit over traditional antiresorptive therapies. However, abaloparatide (synthetic parathyroid-related peptide (PTHrP), Tymlos, Radius Health, Waltham, MA), the second drug in this family, has recently become available for use. In this narrative review, we review the mechanism, effects, and benefits of abaloparatide compared to alternative treatments as well as discuss the current literature in regard to its effect on osteoporosis-related complications in the spine.
骨质疏松症是一种常见且使人虚弱的疾病，其特征是骨量和骨结构减少，导致骨骼脆弱。双膦酸盐（以及较少使用的地舒单抗）等抗吸收药物是骨质疏松症的典型一线治疗药物。然而，新的合成代谢药物已被证明在改善骨量和结构以及降低骨折风险方面的效果优于传统的抗吸收治疗。特立帕肽（人重组甲状旁腺激素（PTH）1-34，Forteo，Ely Lilly，印第安纳波利斯，IN）是美国第一个获批的此类药物，是应用最广泛的合成代谢性骨质疏松症药物，与传统的抗吸收治疗相比，具有显著的益处。然而，阿巴洛帕肽（合成甲状旁腺相关肽（PTHrP），Tymlos，Radius Health，沃尔瑟姆，MA），该家族中的第二种药物，最近已获准使用。在这篇叙述性综述中，我们回顾了阿巴洛帕肽的作用机制、效果和益处，并将其与替代治疗方法进行了比较，同时还讨论了关于其在脊柱相关骨质疏松症并发症方面的当前文献。
